Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C152H232N40O45 |
Molecular Weight | 3339.7095 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 29 / 29 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC4=CN=CN4)C(C)O)C(C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC5=CNC6=C5C=CC=C6)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O
InChI
InChIKey=WRGVLTAWMNZWGT-VQSPYGJZSA-N
InChI=1S/C152H232N40O45/c1-20-78(10)119(145(233)168-81(13)125(213)174-105(63-87-66-162-92-39-28-27-38-90(87)92)134(222)176-101(59-75(4)5)135(223)187-117(76(6)7)143(231)173-95(41-30-32-56-154)142(230)192-152(18,19)148(236)184-93(122(157)210)42-33-57-161-150(158)159)189-136(224)103(60-84-34-23-21-24-35-84)177-131(219)99(50-54-115(206)207)172-130(218)94(40-29-31-55-153)170-124(212)80(12)166-123(211)79(11)167-129(217)98(47-51-110(156)199)169-111(200)68-163-127(215)96(48-52-113(202)203)171-132(220)100(58-74(2)3)175-133(221)102(62-86-43-45-89(198)46-44-86)178-139(227)107(70-193)181-141(229)109(72-195)182-144(232)118(77(8)9)188-138(226)106(65-116(208)209)179-140(228)108(71-194)183-147(235)121(83(15)197)190-137(225)104(61-85-36-25-22-26-37-85)180-146(234)120(82(14)196)186-112(201)69-164-128(216)97(49-53-114(204)205)185-149(237)151(16,17)191-126(214)91(155)64-88-67-160-73-165-88/h21-28,34-39,43-46,66-67,73-83,91,93-109,117-121,162,193-198H,20,29-33,40-42,47-65,68-72,153-155H2,1-19H3,(H2,156,199)(H2,157,210)(H,160,165)(H,163,215)(H,164,216)(H,166,211)(H,167,217)(H,168,233)(H,169,200)(H,170,212)(H,171,220)(H,172,218)(H,173,231)(H,174,213)(H,175,221)(H,176,222)(H,177,219)(H,178,227)(H,179,228)(H,180,234)(H,181,229)(H,182,232)(H,183,235)(H,184,236)(H,185,237)(H,186,201)(H,187,223)(H,188,226)(H,189,224)(H,190,225)(H,191,214)(H,192,230)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H4,158,159,161)/t78-,79-,80-,81-,82+,83+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,117-,118-,119-,120-,121-/m0/s1
Taspoglutide is a glucagon-like peptide-1 agonist was studied in phase III clinical trials for the treatment patients with type 2 diabetes. However, in September 2010 Roche halted Phase III clinical trials due to gastrointestinal intolerability and serious hypersensitivity reactions experienced by some trial participants.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. | 2009 Jul |
|
Subcutaneous Bioavailability of Taspoglutide at 3 Different Injection Sites in Healthy Overweight/Obese Subjects. | 2015 Nov 1 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00909597
taspoglutide 10mg sc weekly
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C98085
Created by
admin on Fri Dec 15 16:00:23 GMT 2023 , Edited by admin on Fri Dec 15 16:00:23 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB32528
Created by
admin on Fri Dec 15 16:00:23 GMT 2023 , Edited by admin on Fri Dec 15 16:00:23 GMT 2023
|
PRIMARY | |||
|
56842233
Created by
admin on Fri Dec 15 16:00:23 GMT 2023 , Edited by admin on Fri Dec 15 16:00:23 GMT 2023
|
PRIMARY | |||
|
C152518
Created by
admin on Fri Dec 15 16:00:23 GMT 2023 , Edited by admin on Fri Dec 15 16:00:23 GMT 2023
|
PRIMARY | |||
|
m10479
Created by
admin on Fri Dec 15 16:00:23 GMT 2023 , Edited by admin on Fri Dec 15 16:00:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
C541736
Created by
admin on Fri Dec 15 16:00:23 GMT 2023 , Edited by admin on Fri Dec 15 16:00:23 GMT 2023
|
PRIMARY | |||
|
2PHK27IP3B
Created by
admin on Fri Dec 15 16:00:23 GMT 2023 , Edited by admin on Fri Dec 15 16:00:23 GMT 2023
|
PRIMARY | |||
|
8975
Created by
admin on Fri Dec 15 16:00:23 GMT 2023 , Edited by admin on Fri Dec 15 16:00:23 GMT 2023
|
PRIMARY | |||
|
275371-94-3
Created by
admin on Fri Dec 15 16:00:23 GMT 2023 , Edited by admin on Fri Dec 15 16:00:23 GMT 2023
|
PRIMARY | |||
|
TASPOGLUTIDE
Created by
admin on Fri Dec 15 16:00:23 GMT 2023 , Edited by admin on Fri Dec 15 16:00:23 GMT 2023
|
PRIMARY | |||
|
DB14027
Created by
admin on Fri Dec 15 16:00:23 GMT 2023 , Edited by admin on Fri Dec 15 16:00:23 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107860
Created by
admin on Fri Dec 15 16:00:23 GMT 2023 , Edited by admin on Fri Dec 15 16:00:23 GMT 2023
|
PRIMARY | |||
|
WW-10
Created by
admin on Fri Dec 15 16:00:23 GMT 2023 , Edited by admin on Fri Dec 15 16:00:23 GMT 2023
|
PRIMARY |
ACTIVE MOIETY